Timmins
Bryan Christopher Timmins, Woodford Halse GB
Patent application number | Description | Published |
---|---|---|
20120279227 | METHOD FOR THE CAPTURE AND DISPOSAL OF CARBON DIOXIDE IN AN ENERGY CONVERSION PROCESS - An energy conversion process that also exports by-product CO | 11-08-2012 |
Cyril Timmins, Solihull GB
Patent application number | Description | Published |
---|---|---|
20120279227 | METHOD FOR THE CAPTURE AND DISPOSAL OF CARBON DIOXIDE IN AN ENERGY CONVERSION PROCESS - An energy conversion process that also exports by-product CO | 11-08-2012 |
David Gary Timmins, Coleshill GB
Patent application number | Description | Published |
---|---|---|
20130039049 | MOBILE LIGHT TOWER - A mobile light tower ( | 02-14-2013 |
John Andrew Timmins, Wolverhampton GB
Patent application number | Description | Published |
---|---|---|
20120267311 | FILTERING MACHINE - A filtering machine ( | 10-25-2012 |
20130068686 | FILTERING MACHINE - A filtering machine ( | 03-21-2013 |
Nicholas Eion Timmins, Basel CH
Patent application number | Description | Published |
---|---|---|
20080311650 | Bioreactor for Tissue Engineering - The present invention relates to a method and apparatus for growing cells in a three-dimensional scaffold. Relative movement of the scaffold and an end cap of the culture chamber results in circulation of the growth medium through the scaffold. The invention is also suited for introduction of cells into a scaffold. The scaffold may be any sort of natural or synthetic material that will support cellular life, including a tissue. | 12-18-2008 |
Nicholas Eion Timmins, St. Lucia AU
Patent application number | Description | Published |
---|---|---|
20100151569 | METHOD OF PRODUCING A POPULATION OF CELLS - A method is provided for producing a population of post-mitotic cells of the neutrophil lineage, which method comprises the ex vivo steps of: (a) providing a population of cells comprising neutrophil progenitor cells; and (b) culturing the population of cells in an animal cell culture medium comprising (i) one or more early acting cytokines and (ii) one or more cytokines that differentiate said progenitor cells into a neutrophil specific lineage, under conditions of low oxidative stress, the culture medium being agitated when the cells are at a cell density at which oxygen transfer via the surface of the culture medium is insufficient for growth of the progenitor cells and the progeny thereof under static conditions, to produce a population of post-mitotic cells of the neutrophil lineage. The resulting population of cells can be used to increase the number of neutrophils in a patient. | 06-17-2010 |
20100285586 | METHOD OF PRODUCING A POPULATION OF CELLS - A method is provided for producing an in vitro or ex vivo method of producing a population of lineage committed haematopoietic progenitor, or mature haematopoietic cells, other than cells of the neutrophil lineage, which method comprises the steps of: (a) providing a population of cells comprising haematopoietic progenitor cells; and (b) culturing the population of cells in an animal cell culture medium comprising one or more cytokines that differentiate said progenitor cells into lineage committed haematopoietic progenitor and/or mature haematopoietic cells, under conditions of low oxidative stress, the culture medium being agitated when the cells are at a cell density at which oxygen transfer via the surface of the culture medium is insufficient for growth of the progenitor cells and the progeny thereof under static conditions, to produce a population of lineage committed haematopoietic progenitor, or mature haematopoietic cells, other than cells of the neutrophil lineage. The resulting population of cells can be used to increase the number of haematopoietic cells in a patient. | 11-11-2010 |
Peter Timmins, Prenton GB
Patent application number | Description | Published |
---|---|---|
20100056540 | STABLE PHARMACEUTICAL COMPOSITION FOR OPTIMIZED DELIVERY OF AN HIV ATTACHMENT INHIBITOR - A pharmaceutical composition contains the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, and hydroxypropyl methyl cellulose (HPMC) having a viscosity of at least about 100 cP, wherein the composition does not contain any enzyme inhibitors. | 03-04-2010 |
Peter Timmins, Moreton GB
Patent application number | Description | Published |
---|---|---|
20120282336 | BILAYER TABLET FORMULATIONS - The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations. | 11-08-2012 |
20130330406 | Bilayer Tablet Formulations - The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations. | 12-12-2013 |
Peter Timmins, Wirral GB
Patent application number | Description | Published |
---|---|---|
20120294936 | REDUCED MASS METFORMIN FORMULATIONS - The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules. | 11-22-2012 |